StageAcquired | Acquired
About Deep Lens
Deep Lens develops a healthcare data platform to match patients to suitable clinical trials and precision therapies. Its platform utilizes AI-based machine learning, natural language processing, workflow, and collaboration tools in a-compliant cloud architecture to accelerate the adoption of new trials. The company was founded in 2017 and is based in Columbus, Ohio. In January 2023, Deep Lens was acquired by Paradigm. The terms of the transaction were not disclosed.
Deep Lens's Product Videos
Compete with Deep Lens?
Ensure that your company and products are accurately represented on our platform.
Expert Collections containing Deep Lens
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Deep Lens is included in 7 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
2019's cohort of the most promising digital health startups transforming the healthcare industry
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Clinical Trials Tech Market Map
This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.
Latest Deep Lens News
Jan 30, 2023
Illustration: Lindsey Bailey/Axios Paradigm, a New York-based clinical trial tech platform, raised $203 million in Series A funding and acquired an oncology patient recruitment startup called Deep Lens. Why it matters Clinical trial recruitment is a costly bottleneck for drug development, yet many patients struggle to access relevant trials. Thus a new class of matchmaking infrastructure startups like Paradigm, whose outsized bankroll could help it quickly catch rivals. Details: Arch Venture Partners and General Catalyst co-led the round, and were joined by F-Prime Capital, Lux Capital, GV, Magnetic Ventures, Mubadala Capital and the American Cancer Society. Deep Lens, based in Columbus, Ohio, had raised over $17 million from firms like AIX Ventures and Northpond Ventures. More, per Digital Health Biz & Tech : "There were 17 deals for digital health companies developing clinical trial tech, collectively valued at nearly $300 million, last year. This potential has drawn interest from drugmakers such as GSK, the British pharmaceutical giant, which signed a four-year deal in September with Medable, a clinical trial software unicorn." Axios on facebook
Deep Lens Frequently Asked Questions (FAQ)
When was Deep Lens founded?
Deep Lens was founded in 2017.
Where is Deep Lens's headquarters?
Deep Lens's headquarters is located at 175 S 3rd Street, Columbus.
What is Deep Lens's latest funding round?
Deep Lens's latest funding round is Acquired.
How much did Deep Lens raise?
Deep Lens raised a total of $17.2M.
Who are the investors of Deep Lens?
Investors of Deep Lens include Paradigm, Bridge Bank, Rev1 Ventures, Sierra Ventures, Ohio TechAngels and 5 more.
Who are Deep Lens's competitors?
Competitors of Deep Lens include 4D Path and 5 more.
Who are Deep Lens's customers?
Customers of Deep Lens include Lantern Pharma and TD2.
Compare Deep Lens to Competitors
Pentavere is an early-stage digital health company working with 6 of the top-10 largest pharmaceutical in the world. The company is the developer of a proprietary artificial intelligence (AI) engine that is proven and validated to transform complex clinical documentation into usable real-world evidence and lifesaving insights. Pentavere’s big pharma customers have deployed its AI technology across their entire value chains to inform strategic decisions and enhance clinical workflows, improving operational efficiencies and saving significant costs. The company was founded in 2016 and is based in Toronto, Ontario.
Syapse develops software for aggregating and structuring biomedical data. It combines data intelligence, insight analytics and applied experience through healthcare organizations looking to transform patients’ lives using real-world evidence. The company was founded in 2008 and is based in San Francisco, California.
nference makes biomedical knowledge computable to solve urgent healthcare problems of biopharmas and medical centers. The company offers EMR data, software products and services, record de-identification, curation of unstructured information, and data creation via digitization of pathology and molecular sequencing. It was founded in 2013 and is based in Cambridge, Massachusetts.
Decode Health is a precision medicine analytics company that fuels collaboration within pharmaceutical, diagnostic, and technology companies. The company leverages its platform and expertise in genomics, clinical data, social determinants of health, and other healthcare data sources, to bring actionable insights into focus quickly. It creates data assets, products, and services that improve patient outcomes and reduce costs. Projects include genomic data creation, biomarker discovery, RNA diagnostics, and broader population health analytics. Decode Health was founded in 2019 and is headquartered in Nashville, Tennessee.
Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.
Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.